source
- Roche's Lunsumio clears Phase 3 hurdle, paving way for broader label in indolent lymphomaRoche announced that its T cell engager Lunsumio successfully met the primary endpoints in a Phase 3 study of a slow growing blood cancer. The trial, conducted in patients with indolent lymphoma,…
- Clinical trial enrollment crisis threatens billions in revenue and patient accessClinical trials are struggling with enrollment, with about 80% missing timelines and less than 5% of eligible adult cancer patients participating. Delays have huge financial impact; each day a pha…